Yescarta Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The yescarta market research report is one of a series of new reports that provides yescarta market statistics, including yescarta industry global market size, regional shares, competitors with a yescarta market share, detailed yescarta market segments, market trends, and opportunities, and any further data you may need to thrive in the yescarta industry. This yescarta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast expansion into new cancer indications, advancements in manufacturing technologies, increasing healthcare reimbursement for gene therapies, growing patient awareness and demand, strategic partnerships in oncology research. Major trends include the expansion of car T-cell therapies to solid tumors, the development of next-generation car T-cell therapies, increasing focus on personalized cancer treatments, advancements in automation for car T-cell production, growing adoption of combination therapies.

The growing incidence of leukemia is expected to drive the growth of the Yescarta market in the future. Leukemia is a form of cancer that affects the blood and bone marrow, causing the abnormal production of white blood cells. The rise in leukemia cases can be attributed to factors such as environmental exposures, genetic mutations, lifestyle changes, and improved detection methods. Yescarta, a cutting-edge CAR T-cell therapy, transforms leukemia treatment by reprogramming a patient’s immune cells to target and eliminate cancerous cells, offering hope for better outcomes in the fight against the disease. For example, in 2024, the American Cancer Society reported that the number of leukemia cases reached 62,770, an increase from 59,610 cases in 2023. As a result, the rising incidence of leukemia is fueling the growth of the Yescarta market.

A key trend in the Yescarta market is the focus on developing advanced biologics such as CAR T-cell therapy to enhance treatment efficacy, expand therapeutic uses, and improve patient outcomes in oncology. CAR T-cell therapy works by modifying a patient’s T cells to target and destroy cancer cells, offering a personalized treatment option with the potential for long-term remission and fewer side effects. For instance, in April 2022, Kite Pharma, a US-based manufacturer of biologics, announced that the U.S. Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) as the initial treatment for relapsed or refractory large B-cell lymphoma (LBCL). This marked the first CAR T-cell therapy approved for this indication, underscoring the ongoing progress in cancer treatment through innovative therapies that harness the body's immune system to fight cancer more effectively.

In December 2022, Kite Pharma, a US-based biotechnology company, expanded its strategic partnership with Daiichi Sankyo Ltd. concerning Yescarta (axicabtagene ciloleucel), an innovative CAR T-cell therapy. Initially formed in 2017, this collaboration aims to improve access to the treatment for patients in Japan who suffer from relapsed or refractory large B-cell lymphoma. Daiichi Sankyo, a pharmaceutical company based in Japan, is focused on developing drugs to enhance patient care in oncology.

The key company operating in the yescarta market is Kite Pharma Inc.(a subsidiary of Gilead Sciences Inc.)

North America was the largest region in the yescarta market in 2024. The regions covered in yescarta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the yescarta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Yescarta (axicabtagene ciloleucel) is a genetically engineered autologous T-cell therapy used to treat specific types of hematologic cancers, including relapsed or refractory large B-cell lymphoma and primary mediastinal B-cell lymphoma in adults. This treatment involves modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that targets CD19 on cancerous B cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Yescarta include large B-cell lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, and follicular lymphoma. Large B-cell lymphoma (LBCL) is an aggressive form of non-Hodgkin lymphoma, a cancer originating in the lymphatic system. Yescarta is distributed through various channels, including hospitals, specialty clinics, and online pharmacies, and is used by a range of patients, including adults and the elderly.

The yescarta market consists of sales of cell-based therapies and intravenous (IV) infusion. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.